207 related articles for article (PubMed ID: 18582378)
1. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.
Fritzsche FR; Wassermann K; Jung M; Tölle A; Kristiansen I; Lein M; Johannsen M; Dietel M; Jung K; Kristiansen G
BMC Cancer; 2008 Jun; 8():179. PubMed ID: 18582378
[TBL] [Abstract][Full Text] [Related]
2. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
[TBL] [Abstract][Full Text] [Related]
3. Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix.
Zubel A; Flechtenmacher C; Edler L; Alonso A
Gynecol Oncol; 2009 Aug; 114(2):332-6. PubMed ID: 19473694
[TBL] [Abstract][Full Text] [Related]
4. ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.
Fan X; Wang Y; Zhang C; Liu L; Yang S; Wang Y; Liu X; Qian Z; Fang S; Qiao H; Jiang T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571068
[TBL] [Abstract][Full Text] [Related]
5. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.
Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y
J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536
[TBL] [Abstract][Full Text] [Related]
6. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.
Jung M; Ramankulov A; Roigas J; Johannsen M; Ringsdorf M; Kristiansen G; Jung K
BMC Mol Biol; 2007 Jun; 8():47. PubMed ID: 17559644
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
Sung SY; Kubo H; Shigemura K; Arnold RS; Logani S; Wang R; Konaka H; Nakagawa M; Mousses S; Amin M; Anderson C; Johnstone P; Petros JA; Marshall FF; Zhau HE; Chung LW
Cancer Res; 2006 Oct; 66(19):9519-26. PubMed ID: 17018608
[TBL] [Abstract][Full Text] [Related]
8. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.
Yao M; Tabuchi H; Nagashima Y; Baba M; Nakaigawa N; Ishiguro H; Hamada K; Inayama Y; Kishida T; Hattori K; Yamada-Okabe H; Kubota Y
J Pathol; 2005 Feb; 205(3):377-87. PubMed ID: 15682440
[TBL] [Abstract][Full Text] [Related]
9. The pleiotropic roles of ADAM9 in the biology of solid tumors.
Oria VO; Lopatta P; Schilling O
Cell Mol Life Sci; 2018 Jul; 75(13):2291-2301. PubMed ID: 29550974
[TBL] [Abstract][Full Text] [Related]
10. ADAM9 decreases in castration resistant prostate cancer and is a prognostic factor for overall survival.
Lin GW; Yao XD; Ye DW; Zhang SL; Dai B; Zhang HL; Ma CG
Chin Med J (Engl); 2012 Nov; 125(21):3800-5. PubMed ID: 23106877
[TBL] [Abstract][Full Text] [Related]
11. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
12. Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9.
Xiang LY; Ou HH; Liu XC; Chen ZJ; Li XH; Huang Y; Yang DH
Tumour Biol; 2017 Jun; 39(6):1010428317709128. PubMed ID: 28639884
[TBL] [Abstract][Full Text] [Related]
13. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.
Kossmann CM; Annereau M; Thomas-Schoemann A; Nicco-Overney C; Chéreau C; Batteux F; Alexandre J; Lemare F
Tumour Biol; 2017 Jul; 39(7):1010428317716077. PubMed ID: 28675123
[TBL] [Abstract][Full Text] [Related]
14. Down-regulated expression of RhoA in human conventional renal cell carcinoma.
Pu YS; Wang CW; Liu GY; Kuo YZ; Huang CY; Kang WY; Shun CT; Lin CC; Wu WJ; Hour TC
Anticancer Res; 2008; 28(4B):2039-43. PubMed ID: 18751372
[TBL] [Abstract][Full Text] [Related]
15. ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126.
Wang J; Zhou Y; Fei X; Chen X; Yan J; Liu B; Zhu Z
Oncol Rep; 2017 Apr; 37(4):2033-2040. PubMed ID: 28260063
[TBL] [Abstract][Full Text] [Related]
16. Changes in expressions of ADAM9, 10, and 17 as well as α-secretase activity in renal cell carcinoma.
Erin N; İpekçi T; Akkaya B; Özbudak İH; Baykara M
Urol Oncol; 2017 Jan; 35(1):36.e15-36.e22. PubMed ID: 27692848
[TBL] [Abstract][Full Text] [Related]
17. Critical function for ADAM9 in mouse prostate cancer.
Peduto L; Reuter VE; Shaffer DR; Scher HI; Blobel CP
Cancer Res; 2005 Oct; 65(20):9312-9. PubMed ID: 16230393
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Cooper C
Eur Urol; 2008 Nov; 54(5):1107-8. PubMed ID: 18061340
[No Abstract] [Full Text] [Related]
20. Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Valentini A; Bernardini S
Eur Urol; 2008 Nov; 54(5):1106-7. PubMed ID: 18061338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
